Summary of Aopumai's Conference Call Company Overview - **Company**: Aopumai - **Industry**: Biopharmaceutical and Cell Culture Products Key Financial Performance - **Revenue**: 178 million CNY, up 23.77% year-on-year [2][10] - **Net Profit**: 37.55 million CNY, up 55.55% year-on-year [2][10] - **Net Profit (Excluding Non-recurring Items)**: 29.57 million CNY, up 76.73% year-on-year [2][10] - **Cash Dividend**: Proposed cash dividend of 2.3 CNY per 10 shares, totaling 26 million CNY, representing 69.56% of net profit [2][10] - **R&D Investment**: 24.14 million CNY, up 56.97%, accounting for 13.58% of revenue [2][11] Business Segments and Growth Drivers - **Cell Culture Products**: Revenue increased by 25.49%, driven by demand from biopharmaceutical and research institutions [2][11] - **CDMO Services**: Revenue grew by 13.24%, with improved international competitiveness and increased collaboration opportunities [3][4] - **International Revenue**: 68 million CNY, up 52%, primarily from commercial pipeline expansions in Russia and Spain [4][23] Operational Highlights - **New Production Capacity**: A new 2000-liter liquid culture medium production line was launched at the Taicang factory [2][6] - **Innovation Recognition**: Awarded "Shanghai Innovative Enterprise Headquarters" title, enhancing brand reputation [6] - **Commercial Pipeline**: Increased from 3 to 11 commercial pipelines, with expectations to reach 13 soon [5] Market Dynamics - **Sustainable Growth**: Orders between 1 million to 5 million CNY contributed nearly 50% of culture medium revenue, indicating strong demand from late-stage clinical and commercialization projects [12][13] - **Product Mix**: The company is focusing on high-margin products and optimizing operational efficiency to enhance profitability [4][27] Future Outlook - **Acquisition Plans**: The acquisition of Pengli Bio is expected to complete in Q4 2025, which will significantly impact expenses and profit margins [4][29] - **CDMO Business Recovery**: Anticipated to achieve breakeven within three years, with potential for earlier success due to the recovery of the innovative drug market [4][30] - **Continued R&D Investment**: The company plans to maintain high R&D spending to drive future growth [28][31] Strategic Initiatives - **Global Expansion**: Continued focus on international market penetration and increasing market share domestically and abroad [9][22] - **Product Development**: Introduction of new products such as transfection reagents and agarose, which are gaining traction in the research sector [17][18] - **Cost Management**: Effective cost control measures are in place to support net profit growth [28][29] Conclusion Aopumai has demonstrated strong financial performance and operational growth in the first half of 2025, with a clear strategy for future expansion and innovation in the biopharmaceutical sector. The company is well-positioned to capitalize on market opportunities while managing costs effectively.

Core Insights - The core viewpoint of the article highlights the significant growth in profits for Aopumai, which outpaced revenue growth, indicating a recovery in the CXO industry [3][4]. Financial Performance - Aopumai reported a revenue of 178 million yuan for the first half of the year, a year-on-year increase of 23.77%, with a net profit attributable to shareholders of 37.54 million yuan, up 55.55% [2]. - The company achieved a remarkable profit growth in the second quarter, with a single-quarter revenue of 94.07 million yuan, a year-on-year increase of 47.21%, and a net profit of 22.88 million yuan, soaring by 401.78% [6]. - The net profit growth rate of 55.55% significantly exceeded the revenue growth rate of 23.77%, showcasing operational efficiency improvements [4]. Revenue Drivers - The primary driver of revenue growth was the continuous advancement of client pipelines and accelerated expansion into overseas markets, with sales of cell culture media products increasing by 25.49% to 155 million yuan, contributing 87.34% of total revenue [7]. - The overseas product sales saw a notable increase of 34.92%, reflecting the effectiveness of the company's internationalization strategy [7]. Cost Management - Aopumai's total operating expenses decreased by 29.71% to 31.21 million yuan, with the expense ratio dropping from 30.92% to 17.56% [9]. - The management expenses saw a significant decline of 34.03%, primarily due to the reclassification of costs related to the CDMO platform from management expenses to operating costs [9]. Cash Flow and Future Outlook - The net cash flow from operating activities reached 61.34 million yuan, a year-on-year increase of 271.78%, indicating strong cash generation capabilities [11]. - The company is preparing for future capacity expansion, supported by robust cash flow and anticipated growth in overseas demand in 2024 [11]. CDMO Segment Challenges - The CDMO segment reported a loss of 10.59 million yuan, with a gross margin of -47.53%, indicating ongoing challenges in achieving profitability [15][17]. - Despite a revenue increase of 13.24% in the CDMO segment, high costs led to significant losses, and the segment has not yet reached a breakeven point [15][17]. Competitive Landscape - Aopumai faces intense competition from established CMO/CDMO giants and multinational pharmaceutical companies, which may hinder its market position and profitability [17][18]. - The company announced plans to acquire 100% of Pengli Bio for 1.451 billion yuan, aiming to integrate cell culture media and preclinical CRO services, with performance commitments for the next three years [18].

Core Insights - The company reported a total revenue of 178 million yuan for the first half of 2025, an increase of 34.14 million yuan compared to the same period last year, representing a year-on-year growth of 23.77% [1] - The net profit attributable to shareholders reached 37.55 million yuan, up by 13.41 million yuan from the previous year, marking a year-on-year increase of 55.55% [1] - The net cash inflow from operating activities was 61.34 million yuan, an increase of 44.84 million yuan year-on-year, achieving a growth of 271.78% [1] Financial Ratios - The latest debt-to-asset ratio stands at 8.23%, a decrease of 0.29 percentage points from the previous quarter [3] - The gross profit margin is reported at 56.84% [3] - The return on equity (ROE) is 1.78%, an increase of 0.64 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.33 yuan, an increase of 0.12 yuan year-on-year, reflecting a growth of 57.14% [3] - The total asset turnover ratio is 0.08 times, an increase of 0.01 times year-on-year, representing a growth of 23.41% [3] - The inventory turnover ratio is 1.17 times, up by 0.08 times from the previous year, indicating a year-on-year increase of 7.52% [3] Shareholder Information - The number of shareholders is 3,212, with the top ten shareholders holding a total of 73.26 million shares, accounting for 64.52% of the total share capital [3] - The largest shareholder is Xiao Zhihua, holding 24.9 million shares [3]

8月22日奥浦迈发布2025半年度分配预案，拟10派2.3元（含税），预计派现金额合计为2611.62万元。派 现额占净利润比例为69.56%，这是公司上市以来，累计第6次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派2.3元（含税） | 0.26 | 0.57 | | 2024.12.31 | 10派2元（含税） | 0.23 | 0.54 | | 2024.06.30 | 10派2.2032元（含税） | 0.25 | 0.56 | | 2023.12.31 | 10派2.304元（含税） | 0.26 | 0.36 | | 2023.06.30 | 10派2.1元（含税） | 0.24 | 0.24 | | 2022.12.31 | 10转增4派6元（含税） | 0.49 | 0.50 | 证券时报·数据宝统计显示，公司今日公布了半年报，共实现营业收入1.78亿元，同比增长23.77%，实 现净利润3754.69万元，同比增长55.55%，基本每股收益为 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-062 上海奥浦迈生物科技股份有限公司 关于公司 2025 年中期利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案的具体内容 根据《上海奥浦迈生物科技股份有限公司2025年半年度报告》（未经审计）， 截至2025年6月30日，上海奥浦迈生物科技股份有限公司（以下简称"公司"或 每股分配比例：拟每 10 股派发现金红利 2.30 元（含税）；不送红股， 不进行资本公积转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确； 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持利润分 配总额不变，相应调整每股利润分配比例，并将另行公告具体调整情况。 本次利润分配预案已经公司第二届董事会第十一次会议、第二届监事会 第十次会议审议通过，同时已经公司 2024 年年度股东大会授权公司董 事会，本次利润分配预案无需再次提交股东大会审议。 "奥浦迈 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-070 上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 36,139,446股。 本次股票上市流通总数为36,139,446股。 本次股票上市流通日期为2025 年 9 月 2 日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会（以下简称"中国证监会"）于2022年6月13日出 具的《关于同意上海奥浦迈生物科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2022〕1232号），同意上海奥浦迈生物科技股份有限公司（以下简 称"奥浦迈"或"公司"）首次公开发行股票的注册申请，并经上海证券交易所同意， 公司首次向社会公众公开发行人民币普通股2,049.5082万股，并于2022年9月2日在 上海证券交易所科创板上市。公司首次公开发行完成后总股本为8,198.0328万股， 其中，有限售条件流通股6,50 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 调整2025年度部分日常关联交易预计额度的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务 管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等相关法律、法规和规范性文件的 规定，对奥浦迈调整 2025 年度部分日常关联交易预计额度的的事项进行了专项 核查，核查情况与意见如下： 一、本次日常关联交易执行及调整情况 公司于 2025 年 4 月 14 日召开第二届董事会第八次会议、第二届监事会第 七次会议以及第二届董事会独立董事专门会议第二次会议分别审议通过了《关 于预计 2025 年度日常关联交易的议案》，同意公司（含子公司）对 2025 年度日 常关联交易额度进行预计，涉及金额合计 446.00 万元，主要用于向相关关联方 购买原材料、向关联方销售商品以及接受关联方提供的技术服务。关联董事肖 志华、张俊杰回避表决，获 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法 律法规和规范性文件的要求，就奥浦迈使用暂时闲置募集资金（含超募资金）进 行现金管理的事项进行了审慎核查，并发表如下核查意见： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海奥浦迈生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕1232 号）核准，公司首次公开 发行股票 2,049.5082 万股，每股发行价格为人民币 80.20 元，募集资金总额为人 民币 1,643,705,576.40 元，扣除各项发行费用后实际募集资金净额为人民币 1,510,944,779.75 元。上述募集资金到位情况已经立信会计师 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等法律法规的相关规定，对奥浦迈首次 公开发行部分限售股上市流通事项进行了核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 6 月 13 日出具的《关于同意上海奥浦迈生物科技股份有限公司首次公开发行股票注册的 批复》（证监许可〔2022〕1232 号），同意上海奥浦迈生物科技股份有限公司 （以下简称"奥浦迈"或者"公司"）首次公开发行股票的注册申请，并经上海证券 交易所同意，公司首次向社会公众公开发行人民币普通股 2,049.5082 万股，并于 2022 年 9 月 2 日在上海证券交易所科创板上市。公司首次公 ...

Core Viewpoint - Shanghai OPM Biosciences Co., Ltd. reported significant growth in revenue and net profit for the first half of 2025, driven by strong market demand and effective cost management [1][6][7]. Financial Performance - The company achieved operating revenue of RMB 177.75 million, a year-on-year increase of 23.77% compared to RMB 143.61 million in the same period last year [6][7]. - Total profit reached RMB 48.85 million, marking a 62.55% increase from RMB 30.05 million in the previous year [6][7]. - Net profit attributable to shareholders was RMB 37.55 million, up 55.55% from RMB 24.14 million in the prior year [6][7]. - The net cash flow from operating activities surged to RMB 61.34 million, a remarkable increase of 271.78% compared to RMB 16.50 million in the same period last year [6][7]. Key Financial Indicators - Basic earnings per share rose to RMB 0.33, reflecting a 57.14% increase from RMB 0.21 in the previous year [7]. - The weighted average return on net assets increased to 1.78%, up from 1.13% [7]. - Research and development expenses accounted for 13.58% of operating revenue, compared to 10.71% in the previous year [7]. Business Development - The company has expanded its product offerings, with 282 confirmed drug development pipelines utilizing its cell culture products, an increase of 35 from the end of 2024 [6][7]. - Service business revenue also improved, showing a growth of 13.24% compared to the previous year [6][7]. Shareholder Returns - The company proposed a cash dividend of RMB 2.30 per 10 shares, contingent on meeting profit distribution conditions for the first half of 2025 [1].